GB201611123D0 - Anti met antibodiesand uses thereof - Google Patents

Anti met antibodiesand uses thereof

Info

Publication number
GB201611123D0
GB201611123D0 GBGB1611123.9A GB201611123A GB201611123D0 GB 201611123 D0 GB201611123 D0 GB 201611123D0 GB 201611123 A GB201611123 A GB 201611123A GB 201611123 D0 GB201611123 D0 GB 201611123D0
Authority
GB
United Kingdom
Prior art keywords
antibodiesand
met
anti met
met antibodiesand
antibodiesand uses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1611123.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AGOMAB THERAPEUTICS BVBA
Original Assignee
Euremab Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euremab Srl filed Critical Euremab Srl
Priority to GBGB1611123.9A priority Critical patent/GB201611123D0/en
Publication of GB201611123D0 publication Critical patent/GB201611123D0/en
Priority to PCT/EP2017/065599 priority patent/WO2018001909A1/en
Priority to RU2022101369A priority patent/RU2022101369A/ru
Priority to NZ789725A priority patent/NZ789725A/en
Priority to EP17735419.8A priority patent/EP3475302A1/en
Priority to RU2018146419A priority patent/RU2765267C2/ru
Priority to KR1020227005547A priority patent/KR102566845B1/ko
Priority to CN202210749235.5A priority patent/CN115057933B/zh
Priority to NZ789721A priority patent/NZ789721A/en
Priority to JP2018569021A priority patent/JP7088853B2/ja
Priority to NZ789717A priority patent/NZ789717A/en
Priority to NZ749578A priority patent/NZ749578A/en
Priority to CA3260141A priority patent/CA3260141A1/en
Priority to AU2017288985A priority patent/AU2017288985B2/en
Priority to MX2019000135A priority patent/MX2019000135A/es
Priority to CN201780040456.2A priority patent/CN109689687B/zh
Priority to KR1020237027102A priority patent/KR102686694B1/ko
Priority to KR1020197002631A priority patent/KR102366667B1/ko
Priority to EP19202060.0A priority patent/EP3674321A3/en
Priority to CA3032496A priority patent/CA3032496A1/en
Priority to BR112018077139A priority patent/BR112018077139A8/pt
Priority to CN202510170332.2A priority patent/CN120005025A/zh
Priority to US16/313,710 priority patent/US11098126B2/en
Priority to US16/921,695 priority patent/US20210347901A9/en
Priority to US17/397,510 priority patent/US12084504B2/en
Priority to JP2022093880A priority patent/JP7546834B2/ja
Priority to US18/538,107 priority patent/US20240228632A9/en
Priority to JP2024074907A priority patent/JP2024096330A/ja
Priority to AU2024205680A priority patent/AU2024205680A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/528—CH4 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
GBGB1611123.9A 2016-06-27 2016-06-27 Anti met antibodiesand uses thereof Ceased GB201611123D0 (en)

Priority Applications (29)

Application Number Priority Date Filing Date Title
GBGB1611123.9A GB201611123D0 (en) 2016-06-27 2016-06-27 Anti met antibodiesand uses thereof
US16/313,710 US11098126B2 (en) 2016-06-27 2017-06-23 Anti-MET antibodies and uses thereof
MX2019000135A MX2019000135A (es) 2016-06-27 2017-06-23 Anticuerpos anti-transicion mesenquimal-epitelial (met) y usos de los mismos.
CN201780040456.2A CN109689687B (zh) 2016-06-27 2017-06-23 抗met抗体及其应用
NZ789725A NZ789725A (en) 2016-06-27 2017-06-23 Anti-met antibodies and uses thereof
EP17735419.8A EP3475302A1 (en) 2016-06-27 2017-06-23 Anti-met antibodies and uses thereof
RU2018146419A RU2765267C2 (ru) 2016-06-27 2017-06-23 Анти-мет антитела и их использование
KR1020227005547A KR102566845B1 (ko) 2016-06-27 2017-06-23 Anti-met 항체 및 그 용도
CN202210749235.5A CN115057933B (zh) 2016-06-27 2017-06-23 抗met抗体及其应用
NZ789721A NZ789721A (en) 2016-06-27 2017-06-23 Anti-met antibodies and uses thereof
JP2018569021A JP7088853B2 (ja) 2016-06-27 2017-06-23 抗ｍｅｔ抗体とその利用
NZ789717A NZ789717A (en) 2016-06-27 2017-06-23 Anti-met antibodies and uses thereof
NZ749578A NZ749578A (en) 2016-06-27 2017-06-23 Anti-met antibodies and uses thereof
CA3260141A CA3260141A1 (en) 2016-06-27 2017-06-23 ANTIBODIES AND THEIR USES
AU2017288985A AU2017288985B2 (en) 2016-06-27 2017-06-23 Anti-MET antibodies and uses thereof
PCT/EP2017/065599 WO2018001909A1 (en) 2016-06-27 2017-06-23 Anti-met antibodies and uses thereof
KR1020197002631A KR102366667B1 (ko) 2016-06-27 2017-06-23 Anti-met 항체 및 그 용도
BR112018077139A BR112018077139A8 (pt) 2016-06-27 2017-06-23 Anticorpos anti-met e seus usos
KR1020237027102A KR102686694B1 (ko) 2016-06-27 2017-06-23 Anti-met 항체 및 그 용도
EP19202060.0A EP3674321A3 (en) 2016-06-27 2017-06-23 Anti-met antibodies and uses thereof
CA3032496A CA3032496A1 (en) 2016-06-27 2017-06-23 Anti-met antibodies and uses thereof
RU2022101369A RU2022101369A (ru) 2016-06-27 2017-06-23 Анти-met антитела и их использование
CN202510170332.2A CN120005025A (zh) 2016-06-27 2017-06-23 抗met抗体及其应用
US16/921,695 US20210347901A9 (en) 2016-06-27 2020-07-06 Methods for promoting pancreatic islet cell growth
US17/397,510 US12084504B2 (en) 2016-06-27 2021-08-09 Anti-MET antibodies and uses thereof
JP2022093880A JP7546834B2 (ja) 2016-06-27 2022-06-09 抗ｍｅｔ抗体とその利用
US18/538,107 US20240228632A9 (en) 2016-06-27 2023-12-13 Anti-met antibodies and uses thereof
JP2024074907A JP2024096330A (ja) 2016-06-27 2024-05-02 抗ｍｅｔ抗体とその利用
AU2024205680A AU2024205680A1 (en) 2016-06-27 2024-08-12 Anti-met antibodies and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1611123.9A GB201611123D0 (en) 2016-06-27 2016-06-27 Anti met antibodiesand uses thereof

Publications (1)

Publication Number Publication Date
GB201611123D0 true GB201611123D0 (en) 2016-08-10

Family

ID=56891586

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1611123.9A Ceased GB201611123D0 (en) 2016-06-27 2016-06-27 Anti met antibodiesand uses thereof

Country Status (13)

Country Link
US (3) US11098126B2 (enExample)
EP (2) EP3475302A1 (enExample)
JP (3) JP7088853B2 (enExample)
KR (3) KR102566845B1 (enExample)
CN (3) CN120005025A (enExample)
AU (2) AU2017288985B2 (enExample)
BR (1) BR112018077139A8 (enExample)
CA (2) CA3032496A1 (enExample)
GB (1) GB201611123D0 (enExample)
MX (1) MX2019000135A (enExample)
NZ (4) NZ789717A (enExample)
RU (2) RU2765267C2 (enExample)
WO (1) WO2018001909A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201800000534A1 (it) * 2018-01-03 2019-07-03 Procedimenti per la promozione della crescita cellulare degli isolotti pancreatici.
GB201611123D0 (en) 2016-06-27 2016-08-10 Euremab Srl Anti met antibodiesand uses thereof
IT201800000535A1 (it) 2018-01-03 2019-07-03 Procedimenti per la cura del cancro.
KR102221755B1 (ko) * 2018-05-02 2021-03-02 (주)에임드바이오 c-Met에 특이적으로 결합하는 항체 및 그의 용도
SG11202108311RA (en) 2019-02-26 2021-09-29 Janssen Biotech Inc Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies
US11879013B2 (en) 2019-05-14 2024-01-23 Janssen Biotech, Inc. Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors
JOP20220184A1 (ar) 2020-02-12 2023-01-30 Janssen Biotech Inc علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14
JP2024515266A (ja) 2021-04-08 2024-04-08 ビョンディス・ビー．ブイ． 抗ｃ－ＭＥＴ抗体及び抗体薬物複合体
EP4340937A1 (en) 2021-05-21 2024-03-27 Emblation Limited Microwave treatment of tissue
WO2025163490A1 (en) * 2024-01-30 2025-08-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Growth factor receptor agonist/antagonist

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5587309A (en) 1994-04-29 1996-12-24 The United States Of America As Represented By The Department Of Health And Human Services Method of stimulating proliferation and differentiation of human fetal pancreatic cells ex vivo
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
DE69739856D1 (de) 1996-07-03 2010-06-02 Genentech Inc Agonisten für den rezeptor des hepatozyten-wachstumsfaktors und deren anwendungen
WO2001093899A1 (en) 2000-06-02 2001-12-13 Hiroshi Okamoto PANCREATIC LANGERHANS β CELL PROLIFERATION PROMOTER AND APOPTOSIS INHIBITOR, AND SCREENING OF CANDIDATE COMPOUNDS FOR THE E DRUGS
GB0110430D0 (en) 2001-04-27 2001-06-20 Medical Res Council Protein variants and uses thereof
PL204899B1 (pl) 2001-05-23 2010-02-26 Bristol Myers Squibb Co Zastosowanie rozpuszczalnej zmutowanej cząsteczki CTLA4
ITMI20031127A1 (it) 2003-06-05 2004-12-06 Uni Degli Studi Del Piemont E Orientale Am Anticorpi anti-hgf-r e loro uso
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
JP5068651B2 (ja) * 2004-08-05 2012-11-07 ジェネンテック， インコーポレイテッド ヒト化抗ｃｍｅｔ抗体
DK1981981T3 (da) * 2006-02-06 2011-09-26 Metheresis Translational Res Sa Monoklonalt anti-met antistof, fragmenter og vektorer deraf til behandling af tumorer, samt tilsvarende produkter
AU2011203499B2 (en) 2006-03-30 2013-01-31 Novartis Ag Compositions and methods of use for antibodies of c-Met
WO2008111464A1 (ja) * 2007-03-05 2008-09-18 Eisai R & D Management Co., Ltd. スプライシング異常を指標とする抗ガン剤の作用検定方法
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
US20120190668A1 (en) 2009-08-12 2012-07-26 Oehlen Lambertus J W M Enhancement of cellular transplantation using small moleucle modulators of hepatocyte growth factor (scatter factor) activity
GB2476681B (en) 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
WO2011150454A1 (en) * 2010-06-01 2011-12-08 Monash University ANTIBODIES DIRECTED TO THE UNPROCESSED RECEPTOR TYROSINE KINASE c-MET
BR122014027420A2 (pt) * 2010-11-03 2019-08-20 Argenx Bvba Anticorpos anti c-met
DK2686347T3 (en) * 2011-03-16 2018-06-25 Argenx Bvba Antibodies against CD70
WO2012138599A2 (en) 2011-04-02 2012-10-11 Washington State University Research Foundation Hepatocyte growth factor mimics as therapeutic agents
KR101444837B1 (ko) 2011-06-03 2014-09-30 한국생명공학연구원 ＨＧＦ 활성을 가지는 ｃ-Ｍｅｔ에 대한 인간항체 및 이의 용도
KR20130036993A (ko) 2011-10-05 2013-04-15 삼성전자주식회사 ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
GB201121914D0 (en) * 2011-12-20 2012-02-01 Ge Healthcare Ltd Method for patient selection
WO2013175276A1 (en) * 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
KR101615619B1 (ko) 2014-08-07 2016-04-26 주식회사 파멥신 c-Met 특이적 인간 항체 및 그 제조방법
CA2972048C (en) 2014-12-22 2023-03-07 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof
CN105087468B (zh) 2015-09-01 2018-12-07 东南大学 一种高效诱导干细胞向胰岛β样细胞分化的方法
KR102476846B1 (ko) 2016-02-05 2022-12-12 주식회사 헬릭스미스 항―ｃ―ＭＥＴ 항체 및 이의 용도
IT201800000534A1 (it) 2018-01-03 2019-07-03 Procedimenti per la promozione della crescita cellulare degli isolotti pancreatici.
GB201611123D0 (en) 2016-06-27 2016-08-10 Euremab Srl Anti met antibodiesand uses thereof
IT201800000535A1 (it) 2018-01-03 2019-07-03 Procedimenti per la cura del cancro.

Also Published As

Publication number Publication date
KR102566845B1 (ko) 2023-08-14
AU2017288985B2 (en) 2024-05-16
BR112018077139A2 (pt) 2019-04-30
CA3260141A1 (en) 2025-04-16
JP2022121461A (ja) 2022-08-19
KR102686694B1 (ko) 2024-07-22
US20190315873A1 (en) 2019-10-17
US20240228632A9 (en) 2024-07-11
MX2019000135A (es) 2019-09-26
EP3674321A2 (en) 2020-07-01
US20220153850A1 (en) 2022-05-19
CA3032496A1 (en) 2018-01-04
NZ789725A (en) 2025-11-28
CN109689687B (zh) 2022-07-15
US20240132601A1 (en) 2024-04-25
KR102366667B1 (ko) 2022-02-23
KR20220030306A (ko) 2022-03-10
JP7546834B2 (ja) 2024-09-09
US12084504B2 (en) 2024-09-10
RU2765267C2 (ru) 2022-01-27
BR112018077139A8 (pt) 2022-12-13
KR20230120678A (ko) 2023-08-17
KR20190025938A (ko) 2019-03-12
EP3475302A1 (en) 2019-05-01
RU2018146419A3 (enExample) 2020-09-30
EP3674321A3 (en) 2020-09-30
WO2018001909A1 (en) 2018-01-04
NZ789721A (en) 2025-11-28
NZ749578A (en) 2025-11-28
JP7088853B2 (ja) 2022-06-21
NZ789717A (en) 2025-11-28
US11098126B2 (en) 2021-08-24
RU2018146419A (ru) 2020-06-26
CN115057933B (zh) 2025-02-18
JP2024096330A (ja) 2024-07-12
CN115057933A (zh) 2022-09-16
JP2019524085A (ja) 2019-09-05
CN120005025A (zh) 2025-05-16
RU2022101369A (ru) 2022-02-08
CN109689687A (zh) 2019-04-26
AU2017288985A1 (en) 2019-01-17
AU2024205680A1 (en) 2024-09-19

Similar Documents

Publication Publication Date Title
AU201616678S (en) Cylindres
GB201611123D0 (en) Anti met antibodiesand uses thereof
DK3538786T3 (en) Friktionsmateriale
NO20161702A1 (en) Neckpillow
PL3216505T3 (pl) Mata do zabawy
AU201710580S (en) Bookrack
GB201615968D0 (en) Actuator
GB201704318D0 (en) Staubsauger
GB201603822D0 (en) Li-drive
HUE062333T2 (hu) Állítókar-meghajtás
AU201617244S (en) Case
GB201706055D0 (en) Support-frameworks
IL264437B (en) sets off
GB2558244B (en) De-scaler
GB2555561B (en) Dowhole actuator
GB201612189D0 (en) Quick-Pic
PL3225770T3 (pl) Siłownik
GB201614145D0 (en) FlashBet BetWheel
GB201817064D0 (en) Microtransporters
AU201713060S (en) SUNSHADE - triangle
PH32016001198S1 (en) Brief
PH32016001199S1 (en) Brief
PH32016001200S1 (en) Brief
PH32016001196S1 (en) Brief
PH32016001197S1 (en) Brief

Legal Events

Date Code Title Description
COOA Change in applicant's name or ownership of the application

Owner name: AGOMAB THERAPEUTICS BVBA

Free format text: FORMER OWNER: EUREMAB SRL

AT Applications terminated before publication under section 16(1)